Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - SyntaPharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical companyfocused on discovering, developing, and commercializing smallmolecule drugs to treat severe medical conditions, today announcedencouraging results from the analysis of overall survival (OS) timefor patients in the Company's double-blind, randomized, controlled,multi-center...Synta Pharmaceuticals to Host Conference Call Today
LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - SyntaPharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical companyfocused on discovering, developing, and commercializing smallmolecule drugs to treat severe medical conditions, today announcedit will hold a conference call at 2:30 p.m. (EST) today to discussthese results, which will be presented at the annual meeting of theAmerican Socie...Synta Oncology Candidate STA-4783 Clinical Trial Results to Be Presented at the ASCO Annual Meeting
LEXINGTON, Mass.--(BUSINESS WIRE)--May 23, 2007 - SyntaPharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical companyfocused on discovering, developing, and commercializing smallmolecule drugs to treat severe medical conditions, today announcedthat survival and sub-population data from the Phase 2b clinicaltrial in metastatic melanoma of the Company's lead oncology drugcandidate, STA-478...